Clinical Trials · NCT05514535
A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 573
- Start date
- Aug 2022
- Locations
- 239 sites, 12 countries
- Primary endpoint
- Change in Glycated Haemoglobin (HbA1c) [Noninferiority]